93 related articles for article (PubMed ID: 34036718)
1. Clinicopathological and molecular characterization of chromophobe hepatocellular carcinoma.
Kang HJ; Oh JH; Kim YW; Kim W; An J; Sung CO; Kim J; Shim JH; Hwang S; Yu E; Heaphy CM; Hong SM
Liver Int; 2021 Oct; 41(10):2499-2510. PubMed ID: 34036718
[TBL] [Abstract][Full Text] [Related]
2. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
[TBL] [Abstract][Full Text] [Related]
3. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features.
Wood LD; Heaphy CM; Daniel HD; Naini BV; Lassman CR; Arroyo MR; Kamel IR; Cosgrove DP; Boitnott JK; Meeker AK; Torbenson MS
Mod Pathol; 2013 Dec; 26(12):1586-93. PubMed ID: 23640129
[TBL] [Abstract][Full Text] [Related]
4. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
[No Abstract] [Full Text] [Related]
5. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
[TBL] [Abstract][Full Text] [Related]
6. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
[TBL] [Abstract][Full Text] [Related]
7. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
[TBL] [Abstract][Full Text] [Related]
8. Alternative lengthening of telomeres: mechanism and the pathogenesis of cancer.
Mori JO; Keegan J; Flynn RL; Heaphy CM
J Clin Pathol; 2024 Jan; 77(2):82-86. PubMed ID: 37890990
[TBL] [Abstract][Full Text] [Related]
9. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
[TBL] [Abstract][Full Text] [Related]
10. Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.
Mäkinen N; Aavikko M; Heikkinen T; Taipale M; Taipale J; Koivisto-Korander R; Bützow R; Vahteristo P
PLoS Genet; 2016 Feb; 12(2):e1005850. PubMed ID: 26891131
[TBL] [Abstract][Full Text] [Related]
11. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
[TBL] [Abstract][Full Text] [Related]
12. Alternative Lengthening of Telomeres Phenotype Predicts Progression Risk in Noninsulinomas in a Chinese Cohort.
Ban X; Mo S; Lu Z; Jia C; Shao H; Yan J; Chang X; Mao X; Wu Y; Zhang Y; Fan X; Yu S; Chen J
Neuroendocrinology; 2022; 112(5):510-522. PubMed ID: 34348341
[TBL] [Abstract][Full Text] [Related]
13. Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.
Bower K; Napier CE; Cole SL; Dagg RA; Lau LM; Duncan EL; Moy EL; Reddel RR
PLoS One; 2012; 7(11):e50062. PubMed ID: 23185534
[TBL] [Abstract][Full Text] [Related]
14. High-resolution telomere fluorescence in situ hybridization reveals intriguing anomalies in germ cell tumors.
Shekhani MT; Barber JR; Bezerra SM; Heaphy CM; Gonzalez Roibon ND; Taheri D; Reis LO; Guner G; Joshu CE; Netto GJ; Meeker AK
Hum Pathol; 2016 Aug; 54():106-12. PubMed ID: 27085557
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of ATRX or DAXX mutated neuroblastoma.
Kurihara S; Hiyama E; Onitake Y; Yamaoka E; Hiyama K
J Pediatr Surg; 2014 Dec; 49(12):1835-8. PubMed ID: 25487495
[TBL] [Abstract][Full Text] [Related]
16. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
Lovejoy CA; Li W; Reisenweber S; Thongthip S; Bruno J; de Lange T; De S; Petrini JH; Sung PA; Jasin M; Rosenbluh J; Zwang Y; Weir BA; Hatton C; Ivanova E; Macconaill L; Hanna M; Hahn WC; Lue NF; Reddel RR; Jiao Y; Kinzler K; Vogelstein B; Papadopoulos N; Meeker AK;
PLoS Genet; 2012; 8(7):e1002772. PubMed ID: 22829774
[TBL] [Abstract][Full Text] [Related]
17. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
18. Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma.
Ma LJ; Wang XY; Duan M; Liu LZ; Shi JY; Dong LQ; Yang LX; Wang ZC; Ding ZB; Ke AW; Cao Y; Zhang XM; Zhou J; Fan J; Gao Q
J Pathol; 2017 Dec; 243(4):407-417. PubMed ID: 28833123
[TBL] [Abstract][Full Text] [Related]
19. TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.
de Nonneville A; Salas S; Bertucci F; Sobinoff AP; Adélaïde J; Guille A; Finetti P; Noble JR; Churikov D; Chaffanet M; Lavit E; Pickett HA; Bouvier C; Birnbaum D; Reddel RR; Géli V
EMBO Mol Med; 2022 Oct; 14(10):e15859. PubMed ID: 35920001
[TBL] [Abstract][Full Text] [Related]
20. ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.
Jia SW; Fu S; Wang F; Shao Q; Huang HB; Shao JY
World J Gastroenterol; 2014 Jan; 20(1):183-92. PubMed ID: 24415871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]